Join
Live feed
·
PRReleasevia Quantisnow
Kalaris Therapeutics Inc. logo

Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling

ByQuantisnow·Wall Street's wire, on your screen.
KLRS· Kalaris Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KLRS (Kalaris Therapeutics Inc.) and more on Quantisnow.